{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg%2Fm2+dose", "query": { "intervention": "100 mg/m2 dose" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 857, "total_pages": 86, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg%2Fm2+dose&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T19:25:33.391Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05829226", "title": "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML, Adult Recurrent", "MDS" ], "interventions": [ { "name": "LYT-200", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PureTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2022-12-12", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05829226" }, { "nct_id": "NCT00810017", "title": "Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER-2 Positive Metastatic Breast Cancer" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medstar Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2009-02", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2022-05-19", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00810017" }, { "nct_id": "NCT01265849", "title": "Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Oral Cavity", "Squamous Cell Carcinoma of the Soft Palate" ], "interventions": [ { "name": "LI", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Zinc", "type": "DIETARY_SUPPLEMENT" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT", "PROCEDURE", "RADIATION" ], "sponsor": "CEL-SCI Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 928, "start_date": "2010-12", "completion_date": "2020-12-04", "has_results": true, "last_update_posted_date": "2022-08-19", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 5, "location_summary": "Springfield, Illinois • Detroit, Michigan • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Springfield", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265849" }, { "nct_id": "NCT04083898", "title": "Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Isatuximab", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-04-03", "completion_date": "2024-03-07", "has_results": false, "last_update_posted_date": "2024-03-19", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083898" }, { "nct_id": "NCT01998035", "title": "Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoid Malignancies", "Lymphoma", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "RomiDEPsin 10 MG/M2", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 100 MG", "type": "DRUG" }, { "name": "Romidepsin 14 MG/M2", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 200 MG", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 300 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2013-11", "completion_date": "2020-01-06", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998035" }, { "nct_id": "NCT00005908", "title": "Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasm" ], "interventions": [ { "name": "Docetaxel - Dose A", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel - Dose B", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Tamoxifen Citrate", "type": "DRUG" }, { "name": "Capecitabine - Dose B", "type": "DRUG" }, { "name": "Capecitabine - Dose A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2000-06", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2013-03-19", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005908" }, { "nct_id": "NCT02245867", "title": "Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AL Amyloidosis" ], "interventions": [ { "name": "Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 30, "start_date": "2014-10-30", "completion_date": "2017-07-13", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02245867" }, { "nct_id": "NCT01587144", "title": "Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Lucanthone", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-06-19", "completion_date": "2013-04-15", "has_results": false, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 6, "location_summary": "La Jolla, California • Orange, California • Amherst, New York + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Amherst", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01587144" }, { "nct_id": "NCT00795132", "title": "Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukaemia", "Chronic Disease", "Leukemia", "Myelodysplasia", "Lymphoma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Anti-Thymocyte Globulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 47, "start_date": "2004-04", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2013-07-30", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795132" }, { "nct_id": "NCT01252667", "title": "Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 44, "start_date": "2011-01-25", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2020-04-16", "last_synced_at": "2026-09-14T19:25:33.391Z", "location_count": 4, "location_summary": "Aurora, Colorado • New Orleans, Louisiana • Seattle, Washington", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252667" } ] }